Combination of Ginsenoside H and Vinorelbine for Lung Cancer Treatment
Author Information
Author(s): Li Xinxin, Chen Fengfei, Yang Rui, Song Zhaohui, Ma Xiaohui, Sun Li, Yuan Shengtao
Primary Institution: Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University
Hypothesis
Can a combination of Ginsenoside H and Vinorelbine effectively treat recurrence of Non-Small Cell Lung Cancer?
Conclusion
The combination of Ginsenoside H and Vinorelbine significantly reduces tumor recurrence and improves quality of life in lung cancer patients.
Supporting Evidence
- The inhibition rate of the combined treatment of GH and NVB is 74.81%, significantly higher than using them separately.
- 12 metabolites showed significant differences in abundance between treatment groups and the model group.
- The combination treatment improved the quality of life indicators in mice compared to the model group.
Takeaway
This study shows that using two medicines together can help fight lung cancer better than using just one.
Methodology
A mouse model of lung cancer was created, and the effects of Ginsenoside H and Vinorelbine were evaluated on tumor recurrence and metabolite levels.
Limitations
The study was conducted on mice, and results may not directly translate to humans.
Participant Demographics
10-week-old adult male C57BL/6 mice
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website